Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort)
Sponsor: Instituto de Investigación Sanitaria Aragón
Summary
The PURE trial is a prospective multicenter phase II study evaluating the safety and feasibility of ultra-hypofractionated adjuvant pelvic radiotherapy in patients with high-intermediate-risk and high-risk endometrial cancer following surgery. The study investigates a treatment regimen consisting of 27.5 Gy delivered in five fractions using modern image-guided IMRT/VMAT techniques. The primary objective is to assess acute gastrointestinal and genitourinary toxicity according to CTCAE version 5.0.
Official title: Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for High-Intermediate and High-Risk Endometrial Cancer: A Prospective Multicenter Phase II Safety Cohort Study
Key Details
Gender
FEMALE
Age Range
18 Years - 110 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-03-30
Completion Date
2035-03-30
Last Updated
2026-08-25
Healthy Volunteers
No
Conditions
Interventions
Ultra-hypofractionation schedule of 27.5Gy in 5 fractions on image-guided adjuvant pelvic IMRT/VMAT radiotherapy
Classically, the dose prescribed for adjuvant treatment of endometrial cancer were 45-50Gy in conventional fractionation 1.8Gy/fx, in a total 25-28fx. The shedule proposed on this prospective cohort of 27.5Gy in 5 fractions on image-guided adjuvant pelvic IMRT/VMAT radiotherapy.
Locations (1)
Unidad Clínica Multihospitalaria de Oncología Radioterápica de Aragón (UCMORA)
Zaragoza, Zaragoza, Spain